Biocon gets European GMP certification of its insulins facility in Malaysia

8 September 2017
drugs_pills_tablets_big

Indian drugmaker Biocon’s (BSE: 532523) subsidiary in Malaysia, Biocon Sdn Bhd, has been issued a certificate of ´GMP Compliance´ for its insulins manufacturing facility by the HPRA (Ireland) as the representative European Union inspection authority.

The certificate of GMP compliance reflects that the agency considered the site to be in compliance with the principles and guidelines of Good Manufacturing Practices for active substances, sterile drug products and quality control testing operations. Biocon´s Malaysia facility was inspected by the European Medicines Agency in April 2017.

Biocon Malaysia is one of Asia´s largest state-of-the-art integrated insulins manufacturing facilities, set up with an investment of about $275 million, at the BioXcell Biotech Park in Johor, Malaysia. This is the first overseas biopharma manufacturing and research facility of Biocon and it employs over 600 professionals. The facility is designed to manufacture recombinant human insulin and insulin analogs to cater to the needs of people with diabetes in global markets.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics